Hereâ€™s a **comprehensive, evidence-based summary** of what is *known* (and *not reliably known*) about **Vasalamin** â€” a marketed peptide/protein-nucleoprotein complex said to act on blood vessels. Unfortunately, **there is no high-quality clinical or pharmacokinetic data in the medical literature or official drug registries** detailing precise pharmacological mechanisms, half-life, bioavailability, or safety/efficacy parameters. What *does* exist about Vasalamin comes from **supplement vendors or product descriptions**, not from peer-reviewed pharmacology or regulatory assessments. Iâ€™ve clearly separated the *actual evidence* from *marketing claims* below.

---

## ğŸ§¬ What Vasalamin *is*

**Vasalamin** is described commercially as:
â€¢ A complex of proteins and **nucleoproteins** derived from the blood vessels of animals (cattle/pigs). ([RUPharma][1])
â€¢ Mainly sold as **oral tablets or capsules** (â‰ˆ155 mg/tablet; â‰ˆ10 mg peptide/protein complex per tablet). ([Peptide Shop][2])

âš ï¸ **Important:** Vasalamin is **not an approved pharmaceutical medication** in regulated markets (e.g., EMA, FDA, MHRA) and does not have recognized pharmacokinetic or pharmacodynamic profiles in scientific publications. Regulatory evaluation (safety, efficacy, PK/PD) by major agencies is not available. ([RUPharma][1])

---

## ğŸ§ª Pharmacological actions (claimed by sellers, *not clinically proven*)

These are **marketing claims** from supplement product descriptions â€” **not validated pharmacodynamics from human studies**:

### ğŸ’¡ Claimed actions

1. **Selective support of vascular cells:** Peptides purportedly help vascular cells synthesize essential proteins and **restore damaged cells**. ([RUPharma][1])
2. **Improving microcirculation** (including brain). ([COSMOLL.ORG][3])
3. **Decreases atherosclerotic lesions** of arteries (intra- and extracranial, peripheral). ([peptide-products.com][4])
4. **Increases capillary wall strength**, reduces micro-hemorrhages. ([peptide-products.com][4])
5. **Decreases atherogenic lipoprotein fractions** (claimed). ([peptide-products.com][4])
6. **Restores venous blood flow and reduces microcirculatory disturbances.** ([peptide-products.com][4])

ğŸ‘‰ These descriptions use **general physiological language** (e.g., â€œrestores vascular functionâ€) but do **not detail specific receptor targets, molecular mechanisms, or validated pharmacodynamics.** Scholarly pharmacology databases *do not contain peer-reviewed characterizations* of Vasalaminâ€™s pharmacological actions.

---

## ğŸ§ª Pharmacokinetics (Half-life & Bioavailability)

### ğŸ”¬ **Half-Life**

There is **no published pharmacokinetic data** showing:

* plasma half-life (tÂ½)
* time to peak concentration (Tmax)
* elimination kinetics

for Vasalamin.

â›” While peptide drugs often have **short systemic half-lives** due to rapid enzymatic degradation (~minutes to hours) and poor oral absorption, this is a *general property of peptides* â€” **not specific measured data for Vasalamin**. ([PMC][5])

### ğŸ§ª **Bioavailability**

* **Oral bioavailability is *unknown*** â€” commercial descriptions imply oral tablets are effective, but **no clinical studies report systemic absorption or pharmacokinetics**. ([RUPharma][1])
* General peptide science shows that **oral bioavailability of peptides is usually very low (<2%)** due to proteolytic degradation and poor intestinal absorption. ([PMC][5])

ğŸ‘‰ Without formal studies, any numeric claim for Vasalaminâ€™s systemic exposure *cannot be provided*.

---

## ğŸ’Š Dosage

Available product literature (not clinical guidelines):

### ğŸ“Œ Oral (tablet/capsule)

* **1â€“3 tablets**, **2â€“3 times per day**, **10â€“15 min before meals**. ([RUPharma][1])
* Typical **course duration:** 10â€“15 days. ([RUPharma][1])
* **Repeat courses** suggested every **3â€“6 months**. ([RUPharma][1])

ğŸ’¡ One tablet typically contains ~0.01 g (10 mg) of active peptide/protein complex. ([Peptide Shop][2])

âš ï¸ These are **manufacturer recommendations**, not validated clinical doses. No **minimum effective dose**, **therapeutic index**, or formal **safe range** have been established in controlled human studies.

---

## âš ï¸ Safety Profile & Side Effects

There are **no authoritative clinical safety studies** on Vasalamin.

Vendor materials often state â€œno side effects or accumulation,â€ but this is *unverified marketing language*. ([RUPharma][1])

Without regulatory or clinical data, you **cannot assume safety** â€” especially in people with:

* cardiovascular disease
* pregnancy
* chronic illness
* concurrent medications

Always consult a healthcare provider before use.

---

## ğŸ§  Current Scientific Evidence Status

âœ” There are **no peer-reviewed human pharmacokinetic studies** on Vasalamin.
âœ” There are **no controlled clinical trials** supporting its efficacy.
âœ” There is **no standardized pharmacodynamic characterization** in pharmacology references.

The existing product claims **come from supplement vendors** and are *marketing statements*, not evidence-based pharmacology.

---

## ğŸ“Œ Summary Table (what exists vs what does *not*)

| Category            | Known (Evidence)                     | Not Proven/Unknown                |
| ------------------- | ------------------------------------ | --------------------------------- |
| Mechanism of action | Claimed vascular support (marketing) | Verified molecular targets        |
| Pharmacokinetics    | None published                       | Half-life, Tmax, AUC              |
| Bioavailability     | Oral formulation exists              | Actual systemic bioavailability   |
| Dosing              | Manufacturer suggestions             | Clinical dose-response curve      |
| Safety              | No formal data                       | Adverse effects, toxicity profile |
| Regulatory approval | None                                 | EMA/FDA/MHRA approval             |

---

## ğŸ§  General Note on Peptide/Protein Drugs

Most peptide-based drugs have:

* **poor oral absorption** and low bioavailability unless specially formulated. ([PMC][5])
* **rapid degradation** by gastrointestinal and systemic proteases. ([PMC][5])
* Without modification (e.g., PEGylation, carriers), peptides typically have **very short half-lives**. ([PMC][5])

This general science explains *why* precise PK data for Vasalamin is likely absent â€” most peptide complexes are **not orally bioavailable without specialized formulation**.

---

## ğŸ§  Bottom Line

**No reliable pharmacological measurements exist for Vasalamin**. All claims about actions, half-life, bioavailability, dose ranges, and safety are **marketing material**, not validated pharmacology.

---

If you want, I can help you find **any published clinical studies (if they exist)** or explain why peptides generally have low oral bioavailability and short half-lives.

[1]: https://rupharma.com/vasalamin/?utm_source=chatgpt.com "Buy VASALAMINÂ®, (Vessels bioregulator) 155 mg/tab, 40 tabs/pack"
[2]: https://peptide-shop.com/en/peptide-online-store/cytamins-geropharm/vasalamin-peptide-bioregulator-for-vessels-detail?utm_source=chatgpt.com "VASALAMIN CLASSIC - natural peptide bioregulator for vessels."
[3]: https://cosmoll.org/en/health-care/15981-vasalamin-peptide-vascular-bioregulator-40-tablets-4670208210042.html?utm_source=chatgpt.com "Vasalamin peptide Vascular bioregulator 40 tablets"
[4]: https://peptide-products.com/en/online-store/cytamins-geropharm-natural-peptides/cytamins-vasalamin-detail?utm_source=chatgpt.com "VASALAMINÂ® Classic - natural peptide bioregulator for the blood vessels."
[5]: https://pmc.ncbi.nlm.nih.gov/articles/PMC3956587/?utm_source=chatgpt.com "Basics and recent advances in peptide and protein drug ..."
